PICALM Genetic Variant Alters mRNA Expression Without Affecting Protein Levels or Tau Spreading in Alzheimer's

Kunie Ando1, Lidia Lopez-Gutierrez1, Salwa Mansour2

  • 1Alzheimer and Other Tauopathies Research Group, ULB Center for Diabetes Research, Medical Faculty, ULB Neuroscience Institute, Université Libre de Bruxelles (ULB), 808 Route de Lennik, B-1070 Brussels, Belgium.

Cells
|February 12, 2026
PubMed

Insights

Alzheimer

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Genome-wide association studies consistently link PICALM to Alzheimer's disease (AD) risk.
  • The functional impact of the AD-associated variant rs3851179 in PICALM remains unclear.
  • PICALM is a clathrin adaptor protein crucial for endocytosis.

Purpose of the Study:

  • To investigate the expression of PICALM mRNA and protein in post-mortem Alzheimer's disease (AD) brains.
  • To examine the relationship between the AD-associated variant rs3851179 and PICALM expression levels.
  • To assess the impact of reduced PICALM levels on tau pathology in a mouse model.

Main Methods:

  • Analysis of PICALM mRNA and protein levels in post-mortem AD brains stratified by rs3851179 genotype.
  • Measurement of mRNA-to-protein ratios to assess expression efficiency.
  • Utilizing Picalm heterozygous knockout mice to model reduced PICALM levels and assess tau pathology after stereotaxic injection of pathological tau.

Main Results:

  • PICALM mRNA levels were elevated in AD brains, with the protective rs3851179T allele associated with lower mRNA levels.
  • PICALM protein levels were reduced in AD brains.
  • A dissociation between mRNA and protein levels was observed, indicating reduced protein expression efficiency in carriers of the non-protective CC genotype.
  • Reduced PICALM levels in mice did not significantly alter tau pathology progression.

Conclusions:

  • PICALM protein is reduced in Alzheimer's disease (AD) brains, but this reduction does not appear to influence tau pathology spread in the studied mouse model.
  • The Alzheimer's disease (AD) susceptibility associated with PICALM variants likely involves mechanisms beyond tau propagation, potentially related to endocytic, vascular, or autophagy functions.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...